Aug 05, 2022 3:00pm EDT Processa Pharmaceuticals to Host Conference Call to Discuss Its Second Quarter 2022 Results and Provide 2nd Half Clinical Pipeline Update on August 11, 2022, at 4:30 p.m. EST
Aug 04, 2022 9:30am EDT Processa Pharmaceuticals Announces Launch of Website to Increase Awareness of Ulcerative Necrobiosis Lipoidica and to Inform Patients of the ongoing Phase 2B Study of PCS499
Aug 03, 2022 4:00pm EDT Processa Pharmaceuticals Announces Launch of Website (www.Necrobiosislipoidicastudy.com) to Increase Awareness of Ulcerative Necrobiosis Lipoidica and to Inform Patients of the ongoing Phase 2B Study of PCS499
Jul 12, 2022 8:30am EDT Processa Pharmaceuticals to Present at the World Orphan Drug Congress USA, July 11-13, 2022
May 12, 2022 4:20pm EDT Processa Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate Update
May 05, 2022 8:30am EDT Processa Pharmaceuticals to Host Conference Call to Discuss First Quarter 2022 Results and Provide Drug Development Update on May 12, 2022 at 4:30 p.m. EST
Apr 20, 2022 8:30am EDT Processa Pharmaceuticals Doses First Patient in Amended Phase 1B Protocol for PCS6422 Combined with Capecitabine (Next Generation Capecitabine)
Apr 05, 2022 8:30am EDT Processa Pharmaceuticals Announces First Patient Enrolled in the PCS12852 Phase 2A Trial for the Treatment of Gastroparesis
Mar 30, 2022 4:00pm EDT Processa Pharmaceuticals Announces Year-End 2021 Results and Provides Corporate Update
Mar 23, 2022 8:30am EDT Processa Pharmaceuticals To Host Conference Call to Discuss Fourth Quarter 2021 Results and Provide Drug Development Update on March 30 at 4:30 p.m. EST
